Implications of EGFR PharmDx kit for cetuximab eligibility.

Abstract

EGF receptor (EGFR) represents an attractive target for anticancer therapies in a variety of malignant neoplasms, including colorectal, non-small-cell lung, head and neck carcinomas and gliomas. Monoclonal antibodies, such as cetuximab, are directed against the extracellular EGFR domain, whereas small molecules are targeting the intracellular tyrosine… (More)
DOI: 10.1586/14737159.8.2.141

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.